bs-5918R [Primary Antibody]
ANGPTL3 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: ANGPTL3

Immunogen Range: 21-120/460


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 27329

Swiss Prot: Q9Y5C1

Source: KLH conjugated synthetic peptide derived from human ANG5/ANGPTL3

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Angiopoietin-like protein 3 (Angptl3) functions as a potent lipoprotein lipase inhibitor and is an important component of plasma triglyceride homeostasis. Angptl3 also plays a role in adipose formation and angiogenesis through its interaction with integrin ?v)beta(3). It is secreted by the liver and is functionally defined by the C-terminal fibrinogen (FBN)-like domain and an N-terminal coiled-coil domain. Angptl3 regulates circulating triglyceride levels during different nutritional states thereby mediating the feeding/fasting cycle. A deficiency of Angptl3 results in abnormally low lipid levels, and a repression of the protein may be protective against atherosclerosis. Angptl3 may also play an important role in hyperlipidemia in diabetes.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)

Predicted Molecular Weight: 49


Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

HepG2 lysates probed with ANGPTL3 Polyclonal Antibody, Unconjugated (bs-5918R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Lane 1: Human HL-60 cell Lysates; Lane 2: Human HepG2 cell Lysates; Lane 3: Human 293T cell Lysates; Lane 4: Human Raji cell Lysates; Lane 5: Human MOLT4 cell Lysates. Probed with ANGPTL3 polyclonal Antibody, unconjugated (bs-5918R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.